NLRP3 and breast cancer: As oncosuppressor-miR, it decreases BC development by targeting ECT2, PFN2, and NLRP3. As onco-miR, it (i) enhances cell proliferation, migration, invasion, and EMT through Hippo/Yap1or Notch signalling pathways [45], and (ii) regulates lipid metabolism by targeting SCARB1 and HMGCS1 [46].